With this week bringing record highs of COVID-19 infection across the nation, we're revisiting two presentations from the ASCO20 Virtual Scientific Program on the effect of the virus on patients with cancer. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> With this week bringing record highs of COVID-19 infection across the nation, we're revisiting two presentations from the ASCO20 Virtual Scientific Program on the effect of the virus on patients with cancer.
Jul 12, 2023•11 min•Ep. 54
We're hearing from the authors of three high-impact papers on research in prostate cancer presented during the ASCO20 Virtual Scientific Program. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> We're hearing from the authors of three high-impact papers on research in prostate cancer presented during the ASCO20 Virtual Scientific Program.
Jul 12, 2023•14 min•Ep. 53
This week, we'll review two late-breaking abstracts from the ASCO20 Virtual Scientific Program that reported negative results. Both were presented during the plenary program. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll review two late-breaking abstracts from the ASCO20 Virtual Scientific Program that reported negative results. Both were presented during the plenary program.
Jul 12, 2023•11 min•Ep. 52
This week, we'll be hearing from the authors of three late-breaking abstracts presented in the Plenary program at the ASCO20 Virtual Scientific Program. Their findings highlight significant advances in lung cancer, bladder cancer, and colorectal cancer. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll be hearing from the authors of three late-breaking abstracts presented in the Plenary program at the ASCO20 Virtual Scientific Program. Their findings highligh...
Jul 12, 2023•21 min•Ep. 51
In part 2 of our conversation with Dr. Syed Abutalib, Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and Science; and Founder and Co-Editor of Advances in Cell and Gene Therapy, Dr. Abutalib outlines methods of treatment and prevention for coagulation issues in patients with COVID-19, and summarizes the hemat...
Jul 11, 2023•15 min•Ep. 50
This week, we spoke with Dr. Syed Abutalib, Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and Science; and Founder and Co-Editor of Advances in Cell and Gene Therapy. Dr. Abutalib outlines recent data on coagulation issues seen in patients with COVID-19. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11"...
Jul 11, 2023•14 min•Ep. 49
This week, we'll be featuring some research highlights from the AACR Virtual Annual Meeting, including data on a triplet regimen for women with high-risk, HER2-negative breast cancer; findings on immunotherapy combined with targeted therapy for patients with BRAF V600-mutated melanoma; and a paper on trends in the locations of tobacco and vape shops. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll be featuring some research highlights from the AACR Virtual ...
Jul 11, 2023•15 min•Ep. 48
This week, we'll start off with a report that showed that ibrutinib may help to protect patients infected with COVID-19 from pulmonary injury due to the disease. Next, we'll move onto a report from the AACR Virtual Annual Meeting on talazoparib in patients with locally advanced or metastatic HER2-negative germline BRCA -mutated breast cancer. Lastly, we'll review the FDA's approval of niraparib for patients with advanced ovarian cancer. Coverage of stories discussed this week on ascopost.com: P...
Jul 11, 2023•20 min•Ep. 46
The U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we'll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia. Coverage of stories discussed this week on ascopost.com: FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer FDA Ap...
Jul 11, 2023•16 min•Ep. 45
To begin this week, we'll discuss a report that focused on the characteristics and outcomes of patients with both COVID-19 and cancer in Wuhan, China. Next, we'll turn to a paper on the efficacy of stereotactic ablative radiotherapy in men with oligometastatic prostate cancer. Lastly, we'll talk about the FDA's approval of encorafenib plus cetuximab in patients with BRAF V600E–mutated colorectal cancer. Coverage of stories discussed this week on ascopost.com: Outcomes of COVID-19 Infection in Pa...
Jul 11, 2023•16 min•Ep. 44
We begin with an interview with Dr. William A. Wood of the University of North Carolina, Chapel Hill. Dr. Wood is current Chair of the ASH Research Collaborative's Data Hub Oversight Group, and he spoke with us about the new COVID-19 Registry for Malignant Hematology. Next, we'll move onto a report on the relationship between breastfeeding and reduced risk of invasive ovarian cancer. And to round out this week's episode, we'll go over the FDA's approval of lustpatercept-aamt for anemia in patien...
Jul 11, 2023•15 min•Ep. 43
This week, we'll start with a report on end-of-trial findings with a triplet combination treatment for HER2-positive metastatic breast cancer. Then, we'll hear from the director of a comprehensive cancer center on how her institution is handling the coronavirus outbreak. Lastly, we'll discuss the FDA's approval of durvalumab in small cell lung cancer. Coverage of stories discussed this week on ascopost.com: End-of-Study Results From CLEOPATRA: Pertuzumab, Trastuzumab, and Docetaxel in HER2-Posit...
Jul 11, 2023•11 min•Ep. 42
To start off this week, we'll discuss a report from physicians in Washington state about how they're handling cancer care currently in their institutions amid the COVID-19 pandemic. We'll then hear from Dr. Giuseppe Curigliano, who spoke with The ASCO Post from his office in Milan about how Italy is addressing the needs of patients with cancer. Lastly, we'll go over a paper about the reintroduction of a combination regimen when disease progresses after upfront treatment in patients with colorect...
Jul 11, 2023•14 min•Ep. 41
We're covering the topic on everyone's minds—coronavirus. We'll start with the state of the epidemic as it relates to patients with cancer and the preparedness of the institutions that care for them. Next, we'll look at a study from China that examined the impact of COVID-19 on patients with cancer. Then, we'll finish up by discussing an FDA approval of a combination therapy for patients with hepatocellular carcinoma. Coverage of stories discussed this week on ascopost.com: Mitigating the Spread...
Jul 11, 2023•13 min•Ep. 40
We'll begin this week by discussing an article that described the pulmonary pathology of the novel coronavirus, or COVID-19, which was found coincidentally in two patients undergoing surgery for lung cancer. We'll also update you as to upcoming oncology meetings that have been cancelled due to concerns about the virus.We'll then turn to a report that found adjuvant gemcitabine/platinum chemotherapy was associated with improved disease-free survival vs surveillance in patients with locally advanc...
Jul 11, 2023•17 min•Ep. 39
This week, we'll hear from two researchers on findings presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. We'll also review the FDA's approval of isatuximab-irfc as part of a triplet regimen for patients with relapsed or refractory multiple myeloma. Coverage of stories discussed this week on ascopost.com: FDA Approves Isatuximab-irfc–Based Triplet Regimen for Patients With Relapsed or Refractory Multiple Myeloma "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":...
Jul 11, 2023•17 min•Ep. 38
This week, we'll be reviewing data from three influential abstracts presented at the recent 2020 Genitourinary Cancers Symposium in San Francisco—one on a novel, first-in-class, small molecule, hypoxia-inducible factor 2 alpha inhibitor for heavily pretreated patients with metastatic clear cell renal cell carcinoma; the second, on whether pembrolizumab in combination with the antibody-drug conjugate enfortumab vedotin may be an alternative option for platinum-ineligible patients with locally adv...
Jul 11, 2023•14 min•Ep. 37
We'll start off by discussing results from the I-SPY 2 trial on the efficacy of pembrolizumab plus chemotherapy in HER2-negative breast cancer. Then, we'll move on to a report covering racial disparities in diagnostic and treatment technology as related to outcomes in patients with colorectal cancer. Lastly, we'll review a long list of treatments for which the FDA recently granted Priority Review. Coverage of stories discussed this week on ascopost.com: Addition of Pembrolizumab to Neoadjuvant C...
Jul 11, 2023•12 min•Ep. 36
First, we'll discuss a Korean trial that looked at the role of H. pylori infection and gastric cancer risk. Next, we'll turn to a modeling study that examined HPV vaccination and cervical cancer incidence in low-income and lower–middle-income countries. Last this week, we'll look at data presented at the ASCO-SITC Clinical Immuno-Oncology Symposium on reducing the risk for immune checkpoint inhibitor–associated colitis. Coverage of stories discussed this week on ascopost.com: Does Treating Indiv...
Jul 11, 2023•12 min•Ep. 35
This week, we'll be featuring three researchers discussing findings presented at the 2020 Gastrointestinal Cancers Symposium: Dr. Scott Kopetz, of The University of Texas MD Anderson Cancer Center, discusses quality-of-life results from the BEACON CRC trial in BRAF V600E–mutated colorectal cancer; Dr. Brian Wolpin, of Dana-Farber Cancer Institute, talks about the efficacy of a blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal cancer...
Jul 11, 2023•13 min•Ep. 34
The 2020 Gastrointestinal Cancers Symposium took place last weekend, and today, we'll take a deeper dive into findings in pancreatic cancer and colorectal cancer. We'll also review the FDA approval of tazemetostat in epithelioid sarcoma. Coverage of stories discussed this week on ascopost.com: 'Unprecedented' Responses to Cisplatin/Gemcitabine in BRCA -Mutated Advanced Pancreatic Cancer FDA Approves Tazemetostat for Epithelioid Sarcoma "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12...
Jul 11, 2023•13 min•Ep. 33
We'll begin with a study that focused on elevations in cancer incidence among responders to the World Trade Center site after the September 11, 2001 terrorist attacks. We'll then turn to an analysis evaluating the effect of proton pump inhibitor use on decreased cognitive functioning among breast cancer survivors. Lastly, we'll look at a trial that compared detection and grading of prostate cancer with a novel artificial intelligence system vs seasoned experts. Coverage of stories discussed this...
Jul 11, 2023•14 min•Ep. 32
On this episode, we'll hear about a study that examined the impact of the time of day that a patient with advanced melanoma receives an immune checkpoint inhibitor infusion on overall survival. Then, we'll hear about two recent approvals from the FDA—one in relapsed or refractory multiple myeloma, and one for identification of ovarian cancer lesions during surgery. Coverage of stories discussed this week on ascopost.com: Impact of Time of Day of Immune Checkpoint Inhibitor Infusion on Overall Su...
Jul 11, 2023•11 min•Ep. 123
The FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults wit...
Jul 10, 2023•17 min•Ep. 30
In this episode, we'll cover three important presentations from the San Antonio Breast Cancer Symposium. The first reports results from the HER2CLIMB trial on tucatinib, capecitabine, and trastuzumab for patients with HER2-positive metastatic breast cancer; the second discusses phase II findings on the activity of a novel HER2-targeting antibody-drug conjugate in HER2-positive metastatic breast cancer; and the third focuses on a postoperative treatment regimen for hormone receptor–positive, HER2...
Jul 10, 2023•13 min•Ep. 29
On this episode, we hear from the authors of three high-impact abstracts presented at the 2019 ASH Annual Meeting & Exposition. The first paper investigated immunotherapy vs standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia; the second focused on the efficacy of oral azacitidine for acute myeloid leukemia; and the third looked at a triplet regimen for relapsed or refractory multiple myeloma. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> On this e...
Jul 10, 2023•12 min•Ep. 28
This week, we summarize two studies presented at the recent ESMO Asia Congress—one on a novel combination therapy for unresectable liver cancer, and the second on the activity of a Chinese-manufactured trastuzumab biosimilar. We'll also discuss last week's FDA approval of acalabrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma. Coverage of stories discussed this week on ascopost.com: ESMO Asia 2019: Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular ...
Jul 10, 2023•7 min•Ep. 26
According to findings from a phase II trial, the combination of nivolumab and bevacizumab has shown activity in relapsed ovarian cancer—we discuss those findings reported in JAMA Oncology . Next, we'll move on to a session from CHEST 2019 which outlined palliation techniques that may be of use to oncologists and pulmonologists in treating patients with end-stage lung cancer. Finally, we'll discuss two recent FDA drug approvals for patients with hematologic disorders. Coverage of stories discusse...
Jul 10, 2023•20 min•Ep. 25
The ADMIRAL trial evaluated gilteritinib vs salvage chemotherapy in FLT3 -mutated acute myeloid leukemia—we'll discuss recently reported overall survival results from The New England Journal of Medicine. Then, we'll move onto findings from a pooled analysis of the relationship between lung cancer risk and high fiber and yogurt consumption. Last, we'll talk about a recent restructuring of a key office within the FDA. Coverage of stories discussed this week on ascopost.com: ADMIRAL: Gilteritinib v...
Jul 10, 2023•17 min•Ep. 24
This week, we'll review an interim analysis of the CASPIAN trial, which evaluated the addition of durvalumab to etoposide plus platinum chemotherapy for extensive-stage small cell lung cancer. Then, we'll talk about two recently issued guidelines on screening for colorectal cancer. Lastly, we'll summarize some recent FDA approvals and announcements. Coverage of stories discussed this week on ascopost.com: CASPIAN Trial: Addition of Durvalumab to Platinum/Etoposide for First-Line Treatment of Ext...
Jul 10, 2023•15 min•Ep. 23
